IP Library Granted Patent US 7,829,543
Granted Patent B2
US 7,829,543 · App. 10/754,041 · Granted Nov 9, 2010

Substituted polyamines as inhibitors of bacterial efflux pumps

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,829,543
App. No.
10/754,041
Granted
Nov 9, 2010
Kind
B2
Abstract

Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.

Claims (22)

1. An efflux inhibitor, wherein said inhibitor comprises the structure

and pharmaceutically acceptable salts thereof.

2. An efflux pump inhibitor of formula I:

wherein R is methyl, ethyl, butyl, isopentyl, nonyl, benzyl, phenethyl, 2′-Cl-benzyl or pyridylmethyl; and pharmaceutically acceptable salts thereof.

3. A pharmaceutical composition comprising the efflux pump inhibitor of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising the efflux pump inhibitor of claim 2 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a non-antibiotic bactericidal or bacteriostatic first agent and the efflux inhibitor of claim 1 .

6. The composition of claim 5 , wherein said first agent is an antibiotic.

7. The composition of claim 5 , wherein the efflux inhibitor inhibits an acr-like efflux pump.

8. The composition of claim 5 , further comprising a pharmaceutically acceptable carrier.

9. A composition comprising a non-antibiotic bactericidal or bacteriostatic first agent and the efflux inhibitor of claim 2 .

10. The composition of claim 9 , wherein said first agent is an antibiotic.

11. The composition of claim 9 , wherein the efflux pump inhibitor inhibits an acr-like efflux pump.

12. The composition of claim 9 , further comprising a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising an antibiotic and the efflux pump inhibitor of claim 1 .

14. The composition of claim 13 , further comprising a pharmaceutically acceptable carrier.

15. The composition of claim 13 , wherein the antibiotic is a peptide deformylase inhibitor.

16. The composition of claim 14 , wherein the pharmaceutically acceptable carrier is an inhibitor of said efflux pump.

17. A pharmaceutical composition comprising an antibiotic and the efflux pump inhibitor of claim 2 .

18. The composition of claim 17 , further comprising a pharmaceutically acceptable carrier.

19. The composition of claim 17 , wherein the antibiotic is a peptide deformylase inhibitor.

20. The composition of claim 18 , wherein the pharmaceutically acceptable carrier is an inhibitor of said efflux pump.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →